Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics Clinical Trial

Official title:

Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04525209
• Other study ID #: 2020-08-20
• Status: Not yet recruiting
• Start date: October 1, 2020
• Est. completion date: December 31, 2022

Study information

• Verified date: August 2020
• Source: Ruijin Hospital
• Contact: Hao Chen, MD
• Phone: 13003135899
• Email: haochendr[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;

2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

Exclusion Criteria:

1. The inclusion criteria of the above groups were not met;

2. There are few tissue specimens, only enough for clinical diagnosis;

3. Patients are unwilling to conduct follow-up study;

4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Related Conditions & MeSH terms

• Adenocarcinoma
• Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	RUIJIN Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1 — View Citation

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052. Erratum in: Cell. 2019 Nov 14;179(5):1240. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Integrative Proteomic Characterization of PDAC	The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC	Two yeaers